Status:
COMPLETED
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Lead Sponsor:
Seth Gordhandas Sunderdas Medical College
Conditions:
Cushing's Disease
Corticotroph Adenoma
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dop...
Eligibility Criteria
Inclusion
- Patient with Cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology
Exclusion
- Patient's intolerance to drug or known sensitivity to ergot derivatives
- Pregnancy, lactation or female wishing to be pregnant
- Any serious medical illness
- Patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00889525
Start Date
November 1 2007
Last Update
April 29 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seth GSMC & KEM hospital
Mumbai, Maharashtra, India, 4000012